Cargando…
Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380043/ https://www.ncbi.nlm.nih.gov/pubmed/34370008 http://dx.doi.org/10.1242/dmm.049010 |
_version_ | 1783741117725933568 |
---|---|
author | Kropp, Peter A. Bauer, Rosemary Zafra, Isabella Graham, Carina Golden, Andy |
author_facet | Kropp, Peter A. Bauer, Rosemary Zafra, Isabella Graham, Carina Golden, Andy |
author_sort | Kropp, Peter A. |
collection | PubMed |
description | Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health. |
format | Online Article Text |
id | pubmed-8380043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-83800432021-08-31 Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths Kropp, Peter A. Bauer, Rosemary Zafra, Isabella Graham, Carina Golden, Andy Dis Model Mech Review Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health. The Company of Biologists Ltd 2021-08-09 /pmc/articles/PMC8380043/ /pubmed/34370008 http://dx.doi.org/10.1242/dmm.049010 Text en © 2021. Published by The Company of Biologists Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Review Kropp, Peter A. Bauer, Rosemary Zafra, Isabella Graham, Carina Golden, Andy Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title | Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title_full | Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title_fullStr | Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title_full_unstemmed | Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title_short | Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
title_sort | caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380043/ https://www.ncbi.nlm.nih.gov/pubmed/34370008 http://dx.doi.org/10.1242/dmm.049010 |
work_keys_str_mv | AT kropppetera caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths AT bauerrosemary caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths AT zafraisabella caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths AT grahamcarina caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths AT goldenandy caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths |